cancerguard™

To our patients,

Important information about cancer screening

When it comes to cancer, knowledge is power. Now there's a new screening tool that may put more knowledge about cancer in our hands.

The Cancerguard® test can help:

- **Screen** for more than 50 cancer types and subtypes with a simple blood draw[1]
- **Detect** the deadliest cancer types even in early stages, when they are easier to treat[2,3]
- **Expand** screening for cancer types that have no routine screening options today[4]*

How does it work?

The Cancerguard test detects signals of cancer in the blood, which may help provide insight before symptoms ever appear.[2] And it's from the makers of the Cologuard® test, a leader in cancer screening and diagnostics for nearly 30 years.

Screening for cancer is part of staying well

By adding the Cancerguard test to your routine screenings, you're giving yourself more chances to find cancer early — and more reasons to feel confident about your health. Peace of mind is closer than you think.

Take the next step. Talk to your healthcare provider about whether Cancerguard is right for you.

Visit **Cancerguard.com** or call **1-844-870-8870** to learn more.

*Cancers that have guideline-recommended screening: breast, cervical, colorectal, and lung (high risk).

References: 1. Data on file. Cancerguard Cancer Subtype Analysis. MED-REF-01259. Exact Sciences. Madison, WI. September 2025. **2.** Cancerguard Clinician Brochure. Exact Sciences Corporation. Madison, WI. **3.** Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. *CA Cancer J Clin*. 2025;75(1):10-45. **4.** United States Preventive Services Task Force. A and B recommendations. Published 2022. Accessed March 19, 2025. https://uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations

cancerguard™

Important Information about the Cancerguard Test

Rx only. Talk to your healthcare provider to determine if this test is right for you.

The Cancerguard® test is indicated for use in adults ages 50-84 with no known cancer diagnosis in the last three years. It detects alterations in circulating tumor DNA and tumor-associated protein levels which are commonly associated with cancer. The test does not detect all cancers and is not a replacement for existing recommended cancer screening or diagnostic modalities for cancer. Current recommended screening for cancer should also be followed. The test is not indicated for screening of breast and prostate cancer and was not evaluated for the detection of pre-cancerous lesions. Due to the potential for follow-up imaging with IV contrast CT after a positive test result, careful consideration should be given before ordering the Cancerguard test for patients with a history of adverse reactions to iodine based IV contrast or for women who are, may be, or plan to become pregnant.

Results should be interpreted in the context of the patient's medical history, clinical signs, and symptoms. A negative result does not rule out the presence of cancer of any type. A positive Cancerguard® test result means that the blood test identified a cancer signal that may indicate the presence of cancer. This result alone does not confirm the presence of cancer. Further clinical evaluation by a healthcare provider (which may include blood tests such as complete blood count and comprehensive metabolic panel) and follow-up imaging are needed to locate and confirm a diagnosis of cancer or determine that cancer is not present. While there are no established guidelines for imaging following a positive Cancerguard test result, there is a published follow-up workflow based on expert clinician opinion and results from an exploratory, prospective, interventional study [Kisiel et al Life (Basel) 2024 Jul 24; Lennon et al, Science, 2020]. The proposed workflow in the Kisiel et al publication includes an intravenous-contrast enhanced computed tomography (IV contrast CT of chest, abdomen/pelvis, and soft-tissue neck) and if necessary, positron emission tomography-computed tomography (^{18}F FDG PET-CT) from the skull-base to mid-thigh. Alternative follow-up procedures (e.g. targeted imaging, endoscopic procedures, CT without IV-contrast) may be appropriate in the context of the patient's medical history and clinical evaluation [Lennon et al, Science, 2020]. False positive and false negative test results can occur.

The Cancerguard test was developed, and the performance characteristics validated by Exact Sciences Laboratories following College of American Pathologists (CAP) and Clinical Laboratory Improvement Amendments (CLIA) regulations. This test has not been cleared or approved by the US Food and Drug Administration. The test is performed at Exact Sciences Laboratories. Exact Sciences Laboratories is accredited by CAP, certified under CLIA regulations, and qualified to perform high-complexity clinical laboratory testing.

EXACT SCIENCES

EXACT SCIENCES CORPORATION
5505 Endeavor Lane | Madison, WI 53719
ExactSciences.com | 1-844-870-8870